Abstract

Aim: Adrenomedullin (ADM) is a vasodilator, natriuretic and antiproliferative peptide that lowers blood pressure and inhibits cell migration. The expression of cardiac ADM is increased in heart failure (HF). The objective of this study was to investigate and simultaneously compare the levels of probrain natriuretic peptide (pro-BNP) and ADM as a potential marker in patients with HF.
Material and Methods: In this study, plasma levels of probrain natriuretic peptide and ADM were investigated in 90 subjects with systolic heart failure and 90 healthy controls. The results were compared with appropriate statistical methods.
Results: ADM levels were increased in patients with systolic HF with mean levels of 87.7 (81.4–99.7) pg/mL in HF group and 70.8 (65.2–78.7) pg/mL in healthy controls (p < 0.001). Elevated ADM levels in HF were found to demonstrate a positive correlation with New York Heart Association (NYHA) functional classification (r = 0.94, p < 0.001) and pulmonary arterial systolic pressure (PASP) (r = 0.44, p

Key words: Adrenomedullin; systolic heart failure; probrain natriuretic peptide